Zacks Research Has Negative Outlook for AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Zacks Research lowered their Q1 2025 EPS estimates for shares of Agios Pharmaceuticals in a research note issued on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.64) for the quarter, down from their previous estimate of ($1.63). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.72) EPS, FY2025 earnings at ($6.77) EPS, Q1 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.70) EPS.

A number of other analysts also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 1.7 %

AGIO opened at $41.96 on Monday. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The company has a fifty day moving average of $50.09 and a 200-day moving average of $46.84. The stock has a market cap of $2.39 billion, a PE ratio of 3.69 and a beta of 0.80.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AGIO. State Street Corp boosted its holdings in Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the last quarter. D. E. Shaw & Co. Inc. grew its position in Agios Pharmaceuticals by 87.3% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after purchasing an additional 316,100 shares in the last quarter. Vestal Point Capital LP purchased a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $33,767,000. Seven Eight Capital LP bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $1,693,000. Finally, Edgestream Partners L.P. bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $1,814,000.

Insider Activity

In other news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.